Shattuck Labs, Inc. Common Stock
STTKShattuck Labs, Inc. is a biotechnology company focused on developing innovative therapeutics that modulate the immune system. The company leverages its proprietary SIRPα-Fc fusion protein platform to create targeted therapies aimed at treating cancer and autoimmune diseases. Founded to advance immune-modulating agents, Shattuck Labs emphasizes precision medicine approaches in its drug development pipelines.
Company News
Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company, announced the pricing of a $75 million public offering consisting of 10.88 million shares at $4.00 per share and 7.87 million pre-funded warrants at $3.9999 per warrant. The offering is expected to close on June 11, 2026, with underwriters including Leerink Partners, J.P. Morga...
Shattuck Labs, a clinical-stage biotechnology company developing DR3 blocking antibodies, announced the pricing of a public offering of 10.9 million shares at $4.00 per share and 7.9 million pre-funded warrants at $3.9999 per warrant, expected to raise approximately $75 million gross proceeds. The offering is expected to close on June 11, 2026, w...
Shattuck Labs announced encouraging Phase 1 clinical trial results for SL-325, its lead DR3 blocking antibody candidate, showing a potentially best-in-mechanism immunogenicity profile with only 3.7% of participants developing antidrug antibodies, complete DR3 blockade at low doses, and a favorable safety profile. The company plans to initiate the...
Shattuck Labs, a biotechnology company, announced that its CEO will present at the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025. The company's lead program, SL-325, is a potential first-in-class DR3 antagonist antibody designed to treat inflammatory and immune-mediated diseases.
Shattuck Labs, a biotechnology company, announced that its CEO will present a corporate update and participate in one-on-one meetings at the upcoming J.P. Morgan Healthcare Conference.
